With More Vaccines For Low-Income Countries In Mind, Merck Signs JV With Wellcome Trust; India To Be Research And Manufacturing Hub
This article was originally published in PharmAsia News
MUMBAI - New opportunities like preventive vaccines for developing countries are throwing up newer alliances between disparate stakeholders. In one such deal, New Jersey-headquartered Merck has formed a first-of-its-kind equal stake collaboration with Wellcome Trust of the United Kingdom to work on research and development of vaccines that can prevent diseases mainly in low-income countries
You may also be interested in...
Davinder Gill provides an update on the sharpened focus of the New Delhi-based MSD-Wellcome Trust Hilleman Laboratories as it seeks to narrow its research and development focus in developing vaccines for low-income emerging markets.
The vaccines research JV between Merck and Wellcome Trust has undergone major changes in its operations. The new plan is dramatically different from the one envisioned at the launch of the JV and narrows down on fewer disease areas with a predominant presence in enteric illnesses.
MSD India Managing Director K.G. Ananthakrishnan On Disease Management And Taking A Holistic Approach: An Interview With PharmAsia News (Part 2 of 2)
Merck Sharp & Dohme India Managing Director K.G. Ananthakrishnan discusses MSD’s holistic approach to patient care in India, including disease management, physician education and responsible pricing.